Price T Rowe Associates Inc Aerie Pharmaceuticals Inc Transaction History

Price T Rowe Associates Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $79,746 - $190,664	12,519 Added 79.66%	28,234 $428,000
Q2 2022 Aug 15, 2022	BUY	$4.95 - $9.16 $20,804 - $38,499	4,203 Added 36.51%	15,715 $118,000
Q1 2022 May 16, 2022	SELL	$5.64 - $9.8 $10,670 - $18,541	-1,892 Reduced 14.12%	11,512 $105,000
Q4 2021 Feb 14, 2022	SELL	$7.02 - $13.33 $110,214 - $209,281	-15,700 Reduced 53.94%	13,404 $94,000
Q3 2021 Nov 15, 2021	SELL	$11.32 - $16.63 $2,275 - $3,342	-201 Reduced 0.69%	29,104 $332,000
Q2 2021 Aug 16, 2021	BUY	$15.16 - $18.97 $18,980 - $23,750	1,252 Added 4.46%	29,305 $469,000
Q1 2021 May 17, 2021	BUY	$13.12 - $20.9 $682 - $1,086	52 Added 0.19%	28,053 $501,000
Q4 2020 Feb 16, 2021	BUY	$9.12 - $14.49 $255,369 - $405,734	28,001 New	28,001 $378,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.